Anlotinib Not Yet Recruiting Phase 2 Trials for Distantly Metastatic Malignant Neoplasm / Adenocarcinomas / Recurrent Disease / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03591666A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas